Are macrophages in tumors good targets for novel therapeutic approaches?

Molecules and Cells

Volumn 38, Issue 2, 2015, Pages 95-104

  Alahari, Samthosh V ^b   Dong, Shengli ^a   Alahari, Suresh K ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; Invasion; Macrophages; Microenvironment; Migration

Indexed keywords

BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

HUMAN; HYPOXIA; LYMPHANGIOGENESIS; MACROPHAGE; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PROGNOSIS; REGULATORY MECHANISM; REVIEW; TARGET CELL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE;

EID: 84947932903     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2015.2298     Document Type: Review

References (132)

1. Akaogi, J., Yamada, H., Kuroda, Y., Nacionales, D.C., Reeves, W.H., and Satoh, M. (2004). Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J. Leukoc. Biol. 76, 227-236.
2. Allavena, P., Sica, A., Solinas, G., Porta, C., and Mantovani, A. (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66, 1-9.
3. Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., and Vonderheide, R.H. (2012). Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822-835.
4. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Song, W., Li, D., Sharp, L.L., et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616.
5. Biswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889-896.
6. Boissier, S., Magnetto, S., Frappart, L., Cuzin, B., Ebetino, F.H., Delmas, P.D., and Clezardin, P. (1997). Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57, 3890-3894.
7. Boissier, S., Ferreras, M., Peyruchaud, O., Magnetto, S., Ebetino, F.H., Colombel, M., Delmas, P., Delaisse, J.M., and Clezardin, P. (2000). Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949-2954.
8. Bronte, V., and Zanovello, P. (2005). Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5, 641-654.
9. Campbell, M.J., Tonlaar, N.Y., Garwood, E.R., Huo, D., Moore, D.H., Khramtsov, A.I., Au, A., Baehner, F., Chen, Y., Malaka, D.O., et al. (2010). Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res. Treat 128, 703-711.
10. Chan, L.L., Cheung, B.K., Li, J.C., and Lau, A.S. (2010). A role for STAT3 and cathepsin S in IL-10 down-regulation of IFNgamma-induced MHC class II molecule on primary human blood macrophages. J. Leukoc. Biol. 88, 303-311.
11. Chang, C.I., Liao, J.C., and Kuo, L. (2001). Macrophage arginase promotes tumor cell growth and suppresses nitric oxidemediated tumor cytotoxicity. Cancer Res. 61, 1100-1106.
12. Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Liu, B., Deng, H., Wang, F., Lin, L., Yao, H., et al. (2011). CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell 19, 541-555.
13. Chen, C., Shen, Y., Qu, Q.X., Chen, X.Q., Zhang, X.G., and Huang, J.A. (2012). Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp. Cell Res. 319, 96-102.
14. Chiodoni, C., Colombo, M.P., and Sangaletti, S. (2010). Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 29, 295-307.
15. Coffelt, S.B., Hughes, R., and Lewis, C.E. (2009). Tumorassociated macrophages: effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 1796, 11-18.
16. Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., Holen, I., Monkkonen, H., Boccadoro, M., Forni, G., et al. (2009). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J. Cell. Mol. Med. 14, 2803-2815.
17. DeNardo, D.G., Barreto, J.B., Andreu, P., Vasquez, L., Tawfik, D., Kolhatkar, N., and Coussens, L.M. (2009). CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16, 91-102.
18. Denardo, S.J., Wen, X., Handberg, E.M., Bairey Merz, C.N., Sopko, G.S., Cooper-Dehoff, R.M., and Pepine, C.J. (2011). Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women's Ischemia Syndrome Evaluation (WISE) ancillary study. Clin. Cardiol. 34, 483-487.
19. Dijkgraaf, E.M., Heusinkveld, M., Tummers, B., Vogelpoel, L.T., Goedemans, R., Jha, V., Nortier, J.W., Welters, M.J., Kroep, J.R., and van der Burg, S.H. (2013). Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73, 2480-2492.
20. Doedens, A.L., Stockmann, C., Rubinstein, M.P., Liao, D., Zhang, N., DeNardo, D.G., Coussens, L.M., Karin, M., Goldrath, A.W., and Johnson, R.S. (2010). Macrophage expression of hypoxiainducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465-7475.
21. Egeblad, M., and Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
22. Elbarghati, L., Murdoch, C., and Lewis, C.E. (2008). Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology 213, 899-908.
23. Erler, J.T., Bennewith, K.L., Cox, T.R., Lang, G., Bird, D., Koong, A., Le, Q.T., and Giaccia, A.J. (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44.
24. Fong, C.H., Bebien, M., Didierlaurent, A., Nebauer, R., Hussell, T., Broide, D., Karin, M., and Lawrence, T. (2008). An anti-inflammatory role for IKKbeta through the inhibition of “classical” macrophage activation. J. Exp. Med. 205, 1269-1276.
25. Fromigue, O., Lagneaux, L., and Body, J.J. (2000). Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner Res. 15, 2211-2221.
26. Gabrilovich, D.I., and Nagaraj, S. (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
27. Galdiero, M.R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., and Jaillon, S. (2013). Tumor associated macrophages and neutrophils in cancer. Immunobiology 218, 1402-1410.
28. Garcia, M.A., Collado, M., Munoz-Fontela, C., Matheu, A., Marcos-Villar, L., Arroyo, J., Esteban, M., Serrano, M., and Rivas, C. (2006). Antiviral action of the tumor suppressor ARF. EMBO J. 25, 4284-4292.
29. Giraudo, E., Inoue, M., and Hanahan, D. (2004). An aminobisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 114, 623-633.
30. Goede, V., Brogelli, L., Ziche, M., and Augustin, H.G. (1999). Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int. J. Cancer 82, 765-770.
31. Gordon, S. (2003). Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23-35.
32. Gottfried, E., Kunz-Schughart, L.A., Weber, A., Rehli, M., Peuker, A., Muller, A., Kastenberger, M., Brockhoff, G., Andreesen, R., and Kreutz, M. (2008). Expression of CD68 in non-myeloid cell types. Scand J. Immunol. 67, 453-463.
33. Green, J.R. (2002). Bisphosphonates in cancer therapy. Curr. Opin. Oncol. 14, 609-615.
34. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.W., Egan, L.J., Kagnoff, M.F., and Karin, M. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitisassociated cancer. Cell 118, 285-296.
35. Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N.F., Pluddemann, A., Charles, K., Gordon, S., and Balkwill, F.R. (2006). Ovarian cancer cells polarize macrophages toward a tumorassociated phenotype. J. Immunol. 176, 5023-5032.
36. Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C., and Balkwill, F.R. (2008). "Re-educating" tumor-associated macrophages by targeting NFkappaB. J. Exp. Med. 205, 1261-1268.
37. Hagemann, T., Biswas, S.K., Lawrence, T., Sica, A., and Lewis, C.E. (2009). Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB. Blood 113, 3139-3146.
38. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl. J. Med. 369, 134-144.
39. Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70.
40. Hayakawa, Y., Maeda, S., Nakagawa, H., Hikiba, Y., Shibata, W., Sakamoto, K., Yanai, A., Hirata, Y., Ogura, K., Muto, S., et al. (2009). Effectiveness of IkappaB kinase inhibitors in murine colitis-associated tumorigenesis. J. Gastroenterol. 44, 935-943.
41. Heusinkveld, M., and van der Burg, S.H. (2011). Identification andmanipulation of tumor ssociated macrophages in human cancers. J. Transl. Med. 9, 216.
42. + Th1 cells. J. Immunol. 187, 1157-1165.
43. Hiraga, T., Williams, P.J., Ueda, A., Tamura, D., and Yoneda, T. (2004). Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin. Cancer Res. 10, 4559-4567.
44. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl. J. Med. 363, 711-723.
45. Huang, S., Van Arsdall, M., Tedjarati, S., McCarty, M., Wu, W., Langley, R., and Fidler, I.J. (2002). Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J. Natl. Cancer Inst. 94, 1134-1142.
46. Hume, D.A., and MacDonald, K.P. (2011). Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 119, 1810-1820.
47. Hwu, P. (2010). Treating cancer by targeting the immune system. N Engl. J. Med. 363, 779-781.
48. Imtiyaz, H.Z., Williams, E.P., Hickey, M.M., Patel, S.A., Durham, A.C., Yuan, L.J., Hammond, R., Gimotty, P.A., Keith, B., and Simon, M.C. (2010). Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699-2714.
49. Ji, R.C. (2011). Macrophages are important mediators of either tumoror inflammation-induced lymphangiogenesis. Cell. Mol. Life Sci. 69, 897-914.
50. Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252.
51. Jubb, A.M., Soilleux, E.J., Turley, H., Steers, G., Parker, A., Low, I., Blades, J., Li, J.L., Allen, P., Leek, R., et al. (2010). Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am. J. Pathol. 176, 2019-2028.
52. Kakinoki, K., Nakamoto, Y., Kagaya, T., Tsuchiyama, T., Sakai, Y., Nakahama, T., Mukaida, N., and Kaneko, S. (2010). Prevention of intrahepatic metastasis of liver cancer by suicide gene therapy and chemokine ligand 2/monocyte chemoattractant protein-1 delivery in mice. J. Gene Med. 12, 1002-1013.
53. Kambayashi, T., Alexander, H.R., Fong, M., and Strassmann, G. (1995). Potential involvement of IL-10 in suppressing tumorassociated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J. Immunol. 154, 3383-3390.
54. Kim, J., Modlin, R.L., Moy, R.L., Dubinett, S.M., McHugh, T., Nickoloff, B.J., and Uyemura, K. (1995). IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J. Immunol. 155, 2240-2247.
55. Kim, S., Takahashi, H., Lin, W.W., Descargues, P., Grivennikov, S., Kim, Y., Luo, J.L., and Karin, M. (2009). Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102-106.
56. Knowles, H.J., and Harris, A.L. (2007). Macrophages and the hypoxic tumour microenvironment. Front Biosci. 12, 4298-4314.
57. Kuo, M.L., Duncavage, E.J., Mathew, R., den Besten, W., Pei, D., Naeve, D., Yamamoto, T., Cheng, C., Sherr, C.J., and Roussel, M.F. (2003). Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res. 63, 1046-1053.
58. Kurahara, H., Takao, S., Maemura, K., Mataki, Y., Kuwahata, T., Maeda, K., Sakoda, M., Iino, S., Ishigami, S., Ueno, S., et al. (2012). M2-polarized tumor-associated macrophage infiltration of regional lymph nodes is associated with nodal lymphangiogenesis and occult nodal involvement in pN0 pancreatic cancer. Pancreas 42, 155-159.
59. Lamagna, C., Aurrand-Lions, M., and Imhof, B.A. (2006). Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 80, 705-713.
60. Lang, R., Patel, D., Morris, J.J., Rutschman, R.L., and Murray, P.J. (2002). Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169, 2253-2263.
61. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R., and Willoughby, D.A. (2001). Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7, 1291-1297.
62. Leavy, O. (2011). Immunotherapy: Stopping monocytes in their tracks. Nat. Rev. Immunol. 11, 715.
63. Leek, R.D., Lewis, C.E., Whitehouse, R., Greenall, M., Clarke, J., and Harris, A.L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629.
64. Leek, R.D., Hunt, N.C., Landers, R.J., Lewis, C.E., Royds, J.A., and Harris, A.L. (2000). Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 190, 430-436.
65. Leek, R.D., Talks, K.L., Pezzella, F., Turley, H., Campo, L., Brown, N.S., Bicknell, R., Taylor, M., Gatter, K.C., and Harris, A.L. (2002). Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Res. 62, 1326-1329.
66. Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T.I., Donahoe, J.S., Courties, G., Lee, K.M., Kim, J.I., Markmann, J.F., Marinelli, B., et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005-1010.
67. Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., and Rogers, M.J. (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner Res. 13, 581-589.
68. Luedde, T., Beraza, N., Kotsikoris, V., van Loo, G., Nenci, A., De Vos, R., Roskams, T., Trautwein, C., and Pasparakis, M. (2007). Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119-132.
69. MacDonald, K.P., Palmer, J.S., Cronau, S., Seppanen, E., Olver, S., Raffelt, N.C., Kuns, R., Pettit, A.R., Clouston, A., Wainwright, B., et al. (2010). An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissueand tumor-associated macrophages but does not inhibit inflammation. Blood 116, 3955-3963.
70. Maeda, S., Kamata, H., Luo, J.L., Leffert, H., and Karin, M. (2005). IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977-990.
71. Mahmoud, S.M., Lee, A.H., Paish, E.C., Macmillan, R.D., Ellis, I.O., and Green, A.R. (2011). Tumour-infiltrating macrophages and clinical outcome in breast cancer. J. Clin. Pathol. 65, 159-163.
72. Mantovani, A. (2009). Cancer: inflaming metastasis. Nature 457, 36-37.
73. Mantovani, A., and Sica, A. (2010). Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237.
74. Mantovani, A., Sozzani, S., Locati, M., Allavena, P., and Sica, A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555.
75. Mantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related inflammation. Nature 454, 436-444.
76. Martelli, F., Hamilton, T., Silver, D.P., Sharpless, N.E., Bardeesy, N., Rokas, M., DePinho, R.A., Livingston, D.M., and Grossman, S.R. (2001). p19ARF targets certain E2F species for degradation. Proc. Natl. Acad. Sci. USA 98, 4455-4460.
77. Martinez, F.O., Helming, L., and Gordon, S. (2009). Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 27, 451-483.
78. Medrek, C., Ponten, F., Jirstrom, K., and Leandersson, K. (2012). The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 12, 306.
79. Monkkonen, H., Auriola, S., Lehenkari, P., Kellinsalmi, M., Hassinen, I.E., Vepsalainen, J., and Monkkonen, J. (2006). A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147, 437-445.
80. Moore, K.W., de Waal Malefyt, R., Coffman, R.L., and O'Garra, A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683-765.
81. Moreau, M.F., Guillet, C., Massin, P., Chevalier, S., Gascan, H., Basle, M.F., and Chappard, D. (2007). Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem. Pharmacol. 73, 718-723.
82. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M., Pipeleers, D., In’t Veld, P., De Baetselier, P., et al. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739.
83. Mukhtar, R.A., Moore, A.P., Nseyo, O., Baehner, F.L., Au, A., Moore, D.H., Twomey, P., Campbell, M.J., and Esserman, L.J. (2011a). Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res. Treat 130, 635-644.
84. Mundy, G.R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593.
85. Murdoch, C., and Lewis, C.E. (2005). Macrophage migration and gene expression in response to tumor hypoxia. Int. J. Cancer 117, 701-708.
86. Murdoch, C., Giannoudis, A., and Lewis, C.E. (2004). Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234.
87. Murdoch, C., Muthana, M., Coffelt, S.B., and Lewis, C.E. (2008). The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618-631.
88. Murray, P.J., and Wynn, T.A. (2011). Obstacles and opportunities for understanding macrophage polarization. J. Leukoc. Biol. 89, 557-563.
89. Naugler, W.E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A.M., and Karin, M. (2007). Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124.
90. Obeid, E., Nanda, R., Fu, Y.X., and Olopade, O.I. (2013). The role of tumor-associated macrophages in breast cancer progression (review). Int. J. Oncol. 43, 5-12.
91. Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004). NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461-466.
92. Pollard, J.W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71-78.
93. Pollard, J.W. (2009). Trophic macrophages in development and disease. Nat. Rev. Immunol. 9, 259-270.
94. Pomerantz, J., Schreiber-Agus, N., Liegeois, N.J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.W., et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723.
95. Porta, C., Riboldi, E., and Sica, A. (2011). Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 305, 250-262.
96. Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., and Bar-Sagi, D. (2012). Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847.
97. Qi, Y., Gregory, M.A., Li, Z., Brousal, J.P., West, K., and Hann, S.R. (2004). p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431, 712-717.
98. Qing, W., Fang, W.Y., Ye, L., Shen, L.Y., Zhang, X.F., Fei, X.C., Chen, X., Wang, W.Q., Li, X.Y., Xiao, J.C., et al. (2012). Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid 22, 905-910.
99. Raica, M., Cimpean, A.M., and Ribatti, D. (2009). Angiogenesis in pre-malignant conditions. Eur. J. Cancer 45, 1924-1934.
100. Rankin, E.B., and Giaccia, A.J. (2008). The role of hypoxiainducible factors in tumorigenesis. Cell Death Differ 15, 678-685.
101. Restifo, N.P., Dudley, M.E., and Rosenberg, S.A. (2012). Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281.
102. Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A.S., Nizet, V., Johnson, R.S., Haddad, G.G., and Karin, M. (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature453, 807-811.
103. Rodan, G.A., and Fleisch, H.A. (1996). Bisphosphonates: mechanisms of action. J. Clin. Invest. 97, 2692-2696.
104. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M.L., Segura, I., Li, X., Knevels, E., et al. (2011). HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44.
105. Senaratne, S.G., Pirianov, G., Mansi, J.L., Arnett, T.R., and Colston, K.W. (2000). Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J. Cancer 82, 1459-1468.
106. Senaratne, S.G., Mansi, J.L., and Colston, K.W. (2002). The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J. Cancer 86, 1479-1486.
107. Shantsila, E., Wrigley, B., Tapp, L., Apostolakis, S., Montoro-Garcia, S., Drayson, M.T., and Lip, G.Y. (2011). Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. J. Thromb. Haemost. 9, 1056-1066.
108. Sharma, P., Wagner, K., Wolchok, J.D., and Allison, J.P. (2011). Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805-812.
109. Sharpless, N.E. (2005). INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22-38.
110. + TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. Cytokine 59, 352-357.
111. Shirabe, K., Mano, Y., Muto, J., Matono, R., Motomura, T., Toshima, T., Takeishi, K., Uchiyama, H., Yoshizumi, T., Taketomi, A., et al. (2011). Role of tumor-associated macrophages in the progression of hepatocellular carcinoma. Surg. Today 42, 1-7.
112. Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J., and Mantovani, A. (2000). Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J. Immunol. 164, 762-767.
113. Siveen, K.S., and Kuttan, G. (2009). Role of macrophages in tumour progression. Immunol. Lett. 123, 97-102.
114. Steele, R.J., Brown M., and Eremin O. (1985). Characterisation of macrophages infiltrating human mammary carcinomas. Br. J. Cancer 51, 135-138.
115. Stern, P.H. (2007). Antiresorptive agents and osteoclast apoptosis. J. Cell. Biochem. 101, 1087-1096.
116. Stetler-Stevenson, W.G., and Yu, A.E. (2001). Proteases in invasion: matrix metalloproteinases. Semin. Cancer Biol. 11, 143-152.
117. Stott, F.J., Bates, S., James, M.C., McConnell, B.B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K.H., et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014.
118. Stresing, V., Daubine, F., Benzaid, I., Monkkonen, H., and Clezardin, P. (2007). Bisphosphonates in cancer therapy. Cancer Lett. 257, 16-35.
119. Sugimoto, M., Kuo, M.L., Roussel, M.F., and Sherr, C.J. (2003). Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11, 415-424.
120. Swain, S.M., and Arezzo, J.C. (2008). Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin. Adv. Hematol. Oncol. 6, 455-467.
121. Tsuchiyama, T., Nakamoto, Y., Sakai, Y., Mukaida, N., and Kaneko, S. (2008). Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci. 99, 2075-2082.
122. Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., and Era, S. (2005). Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14, 425-431.
123. van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Lowik, C., and Papapoulos, S. (1996). Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98, 698-705.
124. Vicari, A.P., Chiodoni, C., Vaure, C., Ait-Yahia, S., Dercamp, C., Matsos, F., Reynard, O., Taverne, C., Merle, P., Colombo, M.P., et al. (2002). Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196, 541-549.
125. Vonderheide, R.H., and Glennie, M.J. (2013). Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043.
126. Wang, F.Q., So, J., Reierstad, S., and Fishman, D.A. (2005). Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int. J. Cancer 114, 19-31.
127. Winter, M.C., and Coleman, R.E. (2009). Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr. Opin. Oncol. 21, 499-506.
128. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N Engl. J. Med. 369, 122-133.
129. Wu, H., Xu, J.B., He, Y.L., Peng, J.J., Zhang, X.H., Chen, C.Q., Li, W., and Cai, S.R. (2012). Tumor-associated macrophages promote angiogenesis and lymphangiogenesis of gastric cancer. J. Surg. Oncol. 106, 462-468.
130. Ye, X.Z., Xu, S.L., Xin, Y.H., Yu, S.C., Ping, Y.F., Chen, L., Xiao, H.L., Wang, B., Yi, L., Wang, Q.L., et al. (2012). Tumorassociated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J. Immunol. 189, 444-453.
131. Zhao, J.J., Pan, K., Wang, W., Chen, J.G., Wu, Y.H., Lv, L., Li, J.J., Chen, Y.B., Wang, D.D., Pan, Q.Z., et al. (2012a). The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One 7, e33655.
132. Zhao, Q., Kuang, D.M., Wu, Y., Xiao, X., Li, X.F., Li, T.J., and Zheng, L. (2012b). Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J. Immunol. 188, 1117-1124.